GlobeNewswire Inc | Feb 11, 2021 07:00AM EST

February 11, 2021

WATERTOWN, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the Company will participate in the BMO BioPharma Spotlight Series: Proteins Degraders and Other Next Gen Technologies, including a panel discussion, Ligating Competitors for Collaboration in the Protein Degradation Space, on Thursday, February 18, 2021 at 10:30 a.m. ET.

A recording of the panel discussion will be available for replay four hours following the conclusion of the event and can be accessed under Events & Presentations in the Investors section of the companys website at www.c4therapeutics.com. The replay will be archived on the C4T website for at least two weeks following the presentation.

About C4 TherapeuticsC4 Therapeutics (C4T) is a biopharmaceutical company focused on harnessing the bodys natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. This targeted protein degradation approach offers advantages over traditional therapies, including the potential to treat a wider range of diseases, reduce drug resistance, achieve higher potency, and decrease side effects through greater selectivity. To learn more about C4 Therapeutics, visit www.C4Therapeutics.com.

Investor & Media ContactKendra AdamsSVP, Communications & Investor RelationsKendra.Adams@c4therapeutics.com